Pacific BioLabs Acquires Bay Bioanalytical Laboratory

HERCULES, CA – November 1, 2012 – Pacific BioLabs (PBL), The Service Leader in Bioscience Testing, has acquired Bay Bioanalytical Laboratory (BBL), adding analytical and bioanalytical chemistry to PBL's existing in vivo preclinical and microbiological testing services.

"BBL's world-class bioanalytical capabilities will strongly complement our current GLP and GMP services, allowing us to better serve our clients in the pharm, biopharm, and device industries," said Tom Spalding, President of Pacific BioLabs. "For example, we can now perform in-house bioanalysis to support PK/ADME studies, medical device material characterizations, and complete ICH stability programs."

Founded by Bob Cunico in 1991, Bay Bioanalytical Laboratory provides HPLC, GC, LC/MS, and ICP-MS services to the pharmaceutical and biotech industries. "At BBL, we specialize in solving complex bioanalytical problems and method development challenges," said Cunico. "There is tremendous synergy between BBL and PBL, so the combination will be win-win for BBL, PBL, and all our clients."

Bob Cunico will continue as Principal Scientist, Analytical Services at Pacific BioLabs. The primary author of Basic HPLC and CE of Biomolecules, Bob brings more than 30 years of experience as an analytical chemist to his new role at Pacific BioLabs.

Aaron Burke, PBL Director of Business Development, said, "We expect that our clients will be delighted with the expanded technical capabilities of PBL. They will be able to send us more complex and critical studies to better address their needs throughout all phases of development –preclinical, clinical, and post-market. What won't change is the emphasis on fast turnaround time and attentive client service."

"As we consolidate BBL and PBL, quote preparation, sample submission, and reporting procedures will all be streamlined," said Spalding. "Client audits can be consolidated. Like PBL, BBL has an excellent regulatory track record and FDA inspection history. We expect to further enhance both companies' cGMP and GLP compliance systems, to the benefit of all our clients."

Pacific BioLabs will be exhibiting at the American College of Toxicology Annual Meeting November 5-6, and will also be at BIOMEDevice in San Jose December 4-5, to answer questions about the merger and how expanded services can be of benefit to pharmaceutical, biologic, and medical device companies.

For further information, contact:

Aaron Burke

Director of Marketing and Business Development

Pacific BioLabs


[email protected]  

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

PRA Health has hired a former FDA clinical research lead to help run its decentralized study unit.